New blood pressure drug QLS1410 enters first human tests
NCT ID NCT07152444
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial will test a new drug called QLS1410 in 78 healthy adults and people with mild high blood pressure. The main goal is to check safety and how the body processes the drug. Researchers will also look at how food affects the drug and whether it lowers blood pressure. This is a first step to see if the drug is safe enough for larger studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
QLS1410 (a drug that blocks an enzyme involved in blood pressure regulation)
What this could lead to
If successful, this could lead to a new treatment option for people with mild high blood pressure.
What could go wrong
This is a very early Phase 1 trial, so the main goal is safety, not effectiveness. The drug may not work as hoped or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNCONTROLLED HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University Third Hospital
Beijing, China